The authors reply

  • Laura McCullagh
  • , Lesley Tilson
  • , Cathal Walsh
  • , Michael Barry

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)784-785
Number of pages2
JournalPharmacoEconomics
Volume28
Issue number9
DOIs
Publication statusPublished - 2010
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anticoagulants, therapeutic use
  • Antithrombotics, therapeutic use
  • Ardeparin-sodium, therapeutic use
  • Cost-effectiveness
  • Dabigatran-etexilate, therapeutic use
  • Dalteparin-sodium, therapeutic use
  • Deep-vein-thrombosis, prevention
  • Enoxaparin-sodium, therapeutic use
  • Factor-Xa-inhibitors, therapeutic use
  • Fondaparinux-sodium, therapeutic use
  • Low-molecular-weight-heparins, therapeutic use
  • Pulmonary-embolism, prevention
  • Research-and-development
  • Rivaroxaban, therapeutic use
  • Tinzaparin-sodium, therapeutic use
  • Warfarin, therapeutic use

Cite this